Affimed N.V. (Nasdaq: AFMD) is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The company’s Innate Cell Engagers (ICE®), generated from its proprietary ROCK® platform, are bispecific antibodies, which target innate immune cells, e.g. natural killer (NK) cells and macrophages, to destroy tumor cells. Affimed’s ICE® enable a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors with activity demonstrated as monotherapy and when given in combination with NK cells and other I-O therapeutics. Affimed has three active clinical programs focused on solid tumors and blood cancers. The lead candidate Acimtamig (AFM13) is in development for patients with CD30-positive lymphomas. Acimtamig combined with NK cells has demonstrated high objective response rates in heavily pretreated, relapsed / refractory (r/r) Hodkin lymphoma (HL) patients with a manageable safety profile in a clinical trial (AFM13-104). Affimed’s phase 2 study, LuminICE-203, is underway to investigate acimtamig in combination with AlloNK® (also known as AB-101), an off-the-shelf, allogeneic NK cell from Artiva Biotherapeutics, in patients with r/r HL with an exploratory arm planned in patients with r/r/ peripheral T-cell lymphoma (PTCL). AFM24 is in development for epidermal growth factor receptor (EGFR)-expressing solid tumors. Based on the data generated to date, the developmental focus of AFM24 is in combination with the anti-PD-L1 inhibitor atezolizumab in advanced stage EGFR-positive non-small cell lung cancer (NSCLC). AFM28 is being developed for patients with CD123-expressing acute myeloid leukemia (AML) in need of new therapeutic options. A first-in-human Phase 1 clinical study is underway (AFM28-101) and development in combination with allogeneic NK cell therapy is being explored.
View Top Employees from AffimedWebsite | https://www.affimed.com/ |
Ticker | AFMD |
Revenue | $40.4 million |
Funding | $86.4 million |
Employees | 140 (140 on RocketReach) |
Founded | 2000 |
Address | Gottlieb-Daimler Straße 2, Mannheim, Baden-Württemberg 68165, DE |
Phone | +49 4962 21674360 |
Fax | +49 6221 6743649 |
Technologies |
JavaScript,
HTML,
Twitter
+15 more
(view full list)
|
Industry | Biotechnology Research, Pharmaceuticals, Biotechnology, Healthcare, Science and Engineering, Health Care, Therapeutics |
Web Rank | 2 Million |
Keywords | Lymphoma Treatment, Solid Tumors |
SIC | SIC Code 283 Companies, SIC Code 28 Companies |
NAICS | NAICS Code 32541 Companies, NAICS Code 325 Companies, NAICS Code 32 Companies, NAICS Code 3254 Companies |
Looking for a particular Affimed employee's phone or email?
The Affimed annual revenue was $40.4 million in 2024.
Wolfgang Fischer is the COO of Affimed.
140 people are employed at Affimed.
Affimed is based in Mannheim, Baden-Württemberg.
The NAICS codes for Affimed are [32541, 325, 32, 3254].
The SIC codes for Affimed are [283, 28].